^
    CANCER:

    Biliary Tract Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    FGFR inhibitor
    futibatinib
    pemigatinib
    infigratinib
    		0
    FGFR inhibitor
    Debio 1347
    KIN-3248
    ARQ 087
    ICP-192
    ABSK091
    PD1 inhibitor
    pembrolizumab
    nivolumab
    		1
    PD1 inhibitor
    sintilimab
    camrelizumab
    dostarlimab-gxly
    PDR001
    toripalimab-tpzi
    TT-00420
    regorafenib
    		2
    Multi-tyrosine kinase inhibitor
    ponatinib
    cabozantinib tablet
    anlotinib
    pazopanib
    gemcitabine
    		3
    DNA synthesis inhibitor
    cisplatin + gemcitabine
    fosgemcitabine palabenamide
    FF-10502
    4
    Thymidylate synthase inhibitor
    5-fluorouracil
    capecitabine
    HER2 inhibitor
    trastuzumab
    		5
    HER2 inhibitor
    ZW25
    trastuzumab + tucatinib
    trastuzumab-dttb
    trastuzumab-pkrb
    6
    PD-L1 inhibitor
    PD-L1 inhibitor
    durvalumab
    7
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    8
    DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    gemcitabine + albumin-bound paclitaxel
    cisplatin + gemcitabine + albumin-bound paclitaxel
    9
    DNA synthesis inhibitor, DNA cross linking agent
    gemcitabine + oxaliplatin
    10
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    5-fluorouracil + oxaliplatin
    capecitabine + oxaliplatin
    11
    PARP inhibitor
    PARP inhibitor
    olaparib
    12
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    13
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    pertuzumab / trastuzumab / hyaluronidase-zzxf
    14
    MEK inhibitor
    trametinib
    selumetinib
    15
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    16
    IDH1 inhibitor
    ivosidenib
    17
    RET inhibitor
    pralsetinib
    selpercatinib
    18
    EGFR inhibitor
    erlotinib
    panitumumab
    19
    FGFR2 inhibitor
    FGFR2 inhibitor
    RLY-4008
    20
    c-MET inhibitor
    c-MET inhibitor
    capmatinib
    21
    STAB1 inhibitor
    bexmarilimab
    22
    ALK inhibitor
    crizotinib
    23
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    24
    FGFR inhibitor, Tyrosine kinase inhibitor
    infigratinib + PD173074
    25
    EphB4 inhibitor
    sEphB4-HSA
    26
    HER2 exon 20 mutation inhibitor
    BI 1810631
    27
    ERK2 inhibitor, ERK1 inhibitor
    LTT462
    BVD-523
    28
    PRMT5 inhibitor
    MRTX1719
    AMG 193
    29
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    30
    AMPK activator
    metformin
    31
    KRAS G12C inhibitor
    adagrasib
    32
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    33
    VEGF-A inhibitor
    bevacizumab
    34
    mTOR inhibitor
    everolimus
    35
    MDM2-p53 antagonist
    BI 907828
    36
    MEK inhibitor, Multi-tyrosine kinase inhibitor
    trametinib + pazopanib
    37
    HER2 inhibitor, PD1 inhibitor
    trastuzumab + camrelizumab
    38
    PD1 inhibitor, PARP inhibitor
    pembrolizumab + olaparib
    39
    SLC7A5 inhibitor
    JPH203
    40
    HER2 inhibitor, HER3 inhibitor
    MCLA-128
    41
    Trk inhibitor
    Trk inhibitor
    42
    PD-L1 inhibitor, PD1 inhibitor
    PD1 inhibitor + PD-L1 inhibitor
    43
    BRAF inhibitor
    BRAF inhibitor
    44
    Immunotherapy
    Immunotherapy
    FOLFOX
    GC
    GemOx
    		45
    Chemotherapy
    CAPOX
    GEM-CAP
    FP
    XP
    pembrolizumab + lenvatinib
    		46
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib + toripalimab-tpzi
    sintilimab + lenvatinib
    47
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    gemcitabine + capecitabine
    cisplatin + gemcitabine + gimeracil / oteracil / tegafur
    48
    Folate analog, Thymidylate synthase inhibitor, Topoisomerase I inhibitor
    5-fluorouracil + irinotecan + leucovorin calcium
    49
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    50
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    51
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + lapatinib
    52
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    53
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    SHR-A1811
    neratinib
    		54
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    pyrotinib
    ASLAN001
    afatinib
    55
    PD-L1 inhibitor, MEK1 inhibitor
    atezolizumab + cobimetinib
    56
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    57
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + APL-502
    58
    CD137 agonist, HER2 inhibitor
    PRS-343
    59
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    60
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine
    JNJ-0683
    61
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    62
    ROS1 inhibitor, Trk inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor
    repotrectinib
    63
    TGFβ inhibitor, PD-L1 inhibitor
    M7824
    64
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, HER2 inhibitor, HER4 inhibitor, PD1 inhibitor, EGFR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib + pyrotinib
    65
    FGFR inhibitor, PD1 inhibitor
    pembrolizumab + pemigatinib
    66
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    67
    FGFR2 inhibitor, FGFR1 inhibitor, FGFR3 inhibitor
    TT-00434
    HMPL-453
    68
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
    bosutinib
    69
    Src kinase inhibitor, FAK inhibitor
    AZD0530
    70
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    71
    HER2 inhibitor, HER4 inhibitor, PI3K inhibitor, EGFR inhibitor
    AN2025 + ASLAN001
    72
    CDK7 inhibitor
    SY‑079
    73
    FGFR inhibitor, AXL inhibitor
    pemigatinib + TP-0903
    pemigatinib + BGB324
    74
    AXL inhibitor
    TP-0903
    BGB324
    75
    IDH2 inhibitor, IDH1 inhibitor
    NMS-173
    76
    DNA synthesis inhibitor, PD1 inhibitor
    gemcitabine + toripalimab-tpzi
    77
    GCN2 activator
    NXP800
    78
    B7-H4-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AZD8205
    79
    Tyrosine kinase inhibitor
    PD173074
    80
    Tubulin polymerization promoter, DNA synthesis inhibitor
    cisplatin + carboplatin
    81
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    No biomarker
    FGFR2 fusion
    FGFR2 mutation
    FGFR2 rearrangement
    FGFR2 N549H
    FGFR2 translocation
    FGFR2 F276C
    FGFR2 E565A
    FGFR2 E565G
    FGFR2 E565K
    FGFR2 V564F
    FGFR2 V564I
    FGFR2 amplification
    FGFR2 N549K
    FGFR2 V564L
    FGFR2 N549D
    FGFR2 N549T
    FGFR2 C382R
    FGFR2 Y376C
    FGFR2 M540_I541insMM
    FGFR2 overexpression
    HER-2 positive
    HER-2 amplification
    HER-2 expression
    HER-2 overexpression
    HER-2 mutation
    HER-2 S310F
    TMB-H
    BRCA2 mutation
    BRCA2 rearrangement
    BRCA2 overexpression
    BRCA1 mutation
    BRCA1 S451Lfs*20
    BRCA1 Q858
    PALB2 mutation
    BRAF V600E
    BRAF mutation
    BRAF V600
    BRAF wild-type
    BRAF D594G
    BRAF L485W
    BRAF D594N
    PD-L1 expression
    PD-L1 overexpression
    MSI-H/dMMR + PD-L1 expression
    KRAS G12D
    KRAS mutation
    KRAS G12C
    KRAS wild-type
    KRAS G12S
    FGFR2-BICC1 fusion
    IDH1 mutation
    MET amplification
    IDH1 R132
    MET elevation
    IDH1 R132C
    MET exon 14 mutation
    IDH1 R132V
    ERBB3 amplification + ERBB3 mutation
    ERBB3 mutation
    ERBB3 amplification
    FGFR2-TACC3 fusion
    MSI-H/dMMR
    NTRK3 fusion
    RET fusion
    FGFR fusion
    FGFR mutation
    IFNG overexpression
    FGFR3 fusion
    TP53 mutation + FGFR2 rearrangement
    TP53 mutation + FGFR2 fusion
    BAP1 mutation + FGFR2 rearrangement
    BAP1 mutation + FGFR2 fusion
    IDH1 mutation + FGFR2 fusion
    IDH1 mutation + FGFR2 rearrangement
    EFNB2 positive
    EFNB2 negative
    FGFR3 mutation
    IFNG-L
    FGFR expression
    DCK positive
    IL23 elevation
    BRIP1 overexpression
    TGFB1 underexpression
    ITGB2 underexpression
    ERBB3 mutation + HER-2 amplification
    TNFA-L
    BAP1 mutation
    PBRM1 mutation
    KRAS mutation + PD-L1 expression
    ARID1A mutation
    SLC7A5 overexpression
    MAP2K1 mutation
    MTAP deletion
    PD-1 overexpression
    LMNA-NTRK1 fusion + NTRK1 G595R
    FGFR2-KIAA1217 fusion
    MSI-H/dMMR + PD-1 expression + CD8 positive
    VHL mutation
    FGFR2-AHCYL1 fusion
    EHBP1‐MET fusion
    BRCA1 mutation + PD-L1 expression
    NTRK2 fusion
    FGFR2-OGA fusion
    ERRFI1 deletion
    PIK3R1 mutation + FGFR2 rearrangement
    PIK3CB mutation + FGFR2 rearrangement
    PIK3CA mutation + FGFR2 rearrangement
    NCOA4-RET fusion
    BAP1 581-17_585del22 + RAD21 amplification
    FRS2 amplification
    PBRM1 mutation + FGFR2 fusion
    FGFR1 fusion
    FGFR2-POC1B fusion
    MET-TNS3 fusion
    MET-TRIM4 fusion
    FDFT1 rearrangement + FGFR2 rearrangement
    PIK3CA mutation
    TIMP1-L
    POLE mutation
    BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
    CAPZA2-MET fusion + MET amplification
    TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23
    HER-2 negative + PD-L1 expression
    FGFR3-TACC3 fusion
    ATM mutation
    MDM2 amplification
    NRG1 fusion
    IDH2 mutation
    NTRK1 fusion
    CCL5 elevation
    RAD51 overexpression
    FGFR2-ARHGAP24 fusion
    EGFR T790M
    STK11 K262Sfs*25
    ATM S1905Ifs*25 + STK11 K262Sfs*25
    MALT1 expression
    IDH2 R172K
    FGFR1 overexpression
    DDR
    18 gene inflamed T cell signature
    3-gene effector T cell signature
    FGFR2-CLIP1 fusion
    FGFR2-OPTN fusion
    AR overexpression
    NRAS Q61
    GPC1 overexpression
    TP53 mutation
    KIR2DL3 overexpression
    IL1B overexpression
    S100A8 overexpression
    CDK7 overexpression
    EGFR overexpression + HER-2 overexpression
    FGFR2-NRAP fusion
    FGFR2-ZMYM4 fusion
    FGFR2-SORBS1 fusion
    ATP1B1-NRG1 fusion
    YAP1 positive
    FGFR2-CCDC6 fusion
    SRC T341I
    FGFR2-AFF4 fusion
    SMAD4 mutation
    CDKN2A mutation
    IDH1 R132C + PIK3CA E545K + IDH2 R172K
    HER-2 positive + TP53 mutation
    MSI-H/dMMR + TMB-L
    PTEN mutation + MSI-H/dMMR
    VTCN1 underexpression
    CDKN2A deletion